NEW YORK (GenomeWeb News) – Ohio State University today announced it has licensed to Microlin Bio almost 100 issued and pending microRNA patents for the potential development of cancer diagnostics and treatments.

Microlin also licensed a novel nucleic acid delivery technology from OSU to deliver new therapies to cancer patients. The new therapies would be based on the miRNA patents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.